Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

KZR
Kezar Life Sciences, Inc. Common Stock
stock NASDAQ

At Close
May 9, 2025 3:59:30 PM EDT
4.25USD+3.155%(+0.13)137,263
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-4.12)0
After-hours
May 6, 2025 4:13:30 PM EDT
4.15USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 3, 2022
12:15PM EST  Kezar Life Sciences Shares Move Higher; Avidity Capital Partners Fund Reports In 13G Filing A 6.6% Stake In Co   Benzinga
Dec 10, 2021
07:03AM EST  Kezar Appoints Courtney Wallace To Board   RTTNews
07:00AM EST  Kezar Appoints Courtney Wallace to its Board of Directors   Business Wire
Dec 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021   Benzinga
07:24AM EST  Wells Fargo Initiates Coverage On Kezar Life Sciences with Overweight Rating, Announces Price Target of $19   Benzinga
Nov 16, 2021
02:36PM EST  Mid-Afternoon Market Update: Dow Jumps 150 Points; Talkspace Shares Slide   Benzinga
12:07PM EST  Mid-Day Market Update: Crude Oil Down 1%; Kezar Life Sciences Shares Surge   Benzinga
10:21AM EST  Mid-Morning Market Update: Markets Open Higher; Walmart Tops Q3 Expectations   Benzinga
09:47AM EST  HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20   Benzinga
08:31AM EST  The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment   Benzinga
Nov 15, 2021
04:34PM EST  Kezar Life Sciences Reports Interim Results From MISSION Phase 2 Trial In Patients With Lupus Nephritis: Showed 'clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response   Benzinga
04:05PM EST  Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis   Business Wire
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 11, 2021
07:00AM EST  Kezar Life Sciences to Present at the Jefferies London Healthcare Conference   Business Wire
Nov 9, 2021
05:21PM EST  Kezar Life Sciences Q3 EPS $(0.28) Down From $(0.23) YoY   Benzinga
04:05PM EST  Kezar Reports Third Quarter Financial Results and Provides Business Update   Business Wire
Nov 3, 2021
08:00AM EDT  Kezar to Host Virtual Investor and Analyst Day on November 15, 2021   Business Wire
Oct 27, 2021
08:18AM EDT  Kezar Says First Patient Dosed In Phase 1 Trial Of KZR-261 In Advanced Solid Tumor Malignancies   RTTNews
08:10AM EDT  Kezar Announces First Patient Dosed In Phase 1 Trial Of KZR-261 In Advanced Solid Tumor Malignancies   Benzinga
Oct 5, 2021
04:07PM EDT  Kezar Life Sciences Appoints Gitanjali Jain As VP, Investor Relations And External Affairs   RTTNews
04:01PM EDT  Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs   Business Wire
Sep 17, 2021
10:59AM EDT  Kezar Life Sciences Sponsored Study Titled 'KZR-261 in Subjects With Advanced Solid Malignancies' Posted To National Institutes Of Health's ClinicalTrials.gov; Study Not Yet Recruiting   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 8, 2021
01:46PM EDT  Seeing Kezar Life Sciences Block Trade Of 1.2M Shares At $7.75/Share   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:00AM EDT  Kezar Life Sciences to Participate in Two Upcoming Investor Conferences   Business Wire
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 23, 2021
07:06AM EDT  Kezar Life Sciences Completes Enrollment Of Phase 2 PRESIDIO Trial Of KZR-616 In Polymyositis And Dermatomyositis   RTTNews
07:04AM EDT  Kezar Life Sciences Announces Completion Of Enrollment Of Its Phase 2 PRESIDIO Clinical Trial Of KZR-616 In Polymyositis And Dermatomyositis   Benzinga
Aug 12, 2021
04:43PM EDT  Kezar Life Sciences Q2 EPS $(0.25) Down From $(0.22) YoY   Benzinga
04:02PM EDT  Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates   Business Wire
Jul 20, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021   Benzinga
07:53AM EDT  JonesTrading Initiates Coverage On Kezar Life Sciences with Buy Rating, Announces Price Target of $14   Benzinga
Jul 8, 2021
07:01AM EDT  Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021   Business Wire
Jun 8, 2021
07:13AM EDT  Kezar Life Sciences Announces Formation Of Clinical Advisory Committee   Benzinga
Jun 2, 2021
08:20AM EDT  The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements   Benzinga
07:10AM EDT  Kezar To Present Results Of Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021   Benzinga
07:01AM EDT  Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021   Business Wire
Jun 1, 2021
04:01PM EDT  Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors   Business Wire
May 27, 2021
07:00AM EDT  Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference   Business Wire
May 26, 2021
04:01PM EDT  Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021   Business Wire
May 12, 2021
04:16PM EDT  Kezar Life Sciences Q1 EPS $(0.25) Up From $(0.30) YoY   Benzinga
04:01PM EDT  Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates   Business Wire
May 10, 2021
04:01PM EDT  Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work   Business Wire
Apr 12, 2021
10:08AM EDT  Kezar Life Sciences Saturday Morning Announced Preclinical Data With IND Candidate KZR-261 At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting   Business Wire
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 11, 2021
04:04PM EST  Kezar Life Sciences Q4 EPS $(0.22) Up From $(0.50) YoY   Benzinga
04:01PM EST  Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates   Business Wire
Feb 25, 2021
04:01PM EST  Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference   Business Wire
Feb 10, 2021
04:01PM EST  Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference   Business Wire
Jan 7, 2021
04:02PM EST  Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference   Business Wire
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
04:01PM EST  Kezar Life Sciences Added to the Nasdaq Biotechnology Index   Business Wire
Nov 12, 2020
04:05PM EST  Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences   Business Wire
Nov 5, 2020
04:29PM EST  Kezar Life Sciences Q3 EPS $(0.23) Up From $(0.48) YoY   Benzinga
04:01PM EST  Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates   Business Wire
08:54AM EST  Kezar Highlights Presentation Of 'Broad Therapeutic Potential of KZR-616' During ACR Convergence 2020   Benzinga
08:50AM EST  Kezar Life Highlights Broad Therapeutic Potential Of KZR-616   RTTNews
08:46AM EST  Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020   Business Wire
Oct 23, 2020
07:05AM EDT  Kezar Life Sciences Announces Orphan Drug Designations For KZR-616 For Polymyositis And Dermatomyositis   RTTNews
07:01AM EDT  Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis   Benzinga
06:20AM EDT  Kezar Life Sciences Received FDA Orphan Drug Designation on October 23 for Treatment of Dermatomyositis   Benzinga
Oct 22, 2020
06:28AM EDT  Kezar Life Sciences on Wednesday Received FDA Orphan Drug Designation for their Treatment for Polymyositis   Benzinga
05:40AM EDT  Kezar Life Sciences on Wednesday Received FDA Orphan Drug Designation for their Treatment for Polymyositis on October 21   Benzinga
Oct 15, 2020
07:00AM EDT  Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences   Business Wire
Sep 17, 2020
07:01PM EDT  After Market Hours: Sonoma Pharmaceuticals, Ashford   RTTNews
04:02PM EDT  Kezar Highlights Data From MISSION Phase 1b Study Of KZR-161 During The Pan American Congress Of Rheumatology   Benzinga
Aug 5, 2020
04:15PM EDT  Kezar Life Sciences Q2 EPS $(0.22) Beats $(0.26) Estimate   Benzinga
04:01PM EDT  Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update   Business Wire
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Aug 3, 2020
04:01PM EDT  Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences   Business Wire
Jul 29, 2020
05:17PM EDT  Kezar Life Sciences to Release Second Quarter Financial Results and General Business Updates on August 5, 2020   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC